SLC1A2 and central nervous system cancer: In parallel, a significant decrease in GLT-1 mRNA expression was noted in C6 glioma cells of DEX-treated group compared with vehicle-treated group (24 hours: F1,18 = 6.2; P < 0.05; 48 hours: F1,18 = 6.4; P < 0.05; Figure 5C), whereas GLAST mRNA level was not altered by DEX treatment (24 hours: F1,18 = 1.1; P = 0.31; 48 hours: F1,18 = 0.1; P = 0.86; Figure 5D).